A Leading Provider of Drug & Alcohol Testing Solutions

State-of-the-art specimen testing laboratory offering FDA-cleared Hair, Drug & Oral Fluids Testing. Forensic Testing Accredited to ISO/IEC 17025 Standards.

Reliable Hair, Oral Fluid, & Breath Testing | Omega Laboratories

Home

MOGADORE, Ohio and VANCOUVER, BC, July 8, 2026 /PRNewswire/ -- <a title="Download a copy of the PDF - Omega Laboratories and Cannabix Technologies Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection" href="http://res.cloudinary.com/dnginndga/image/upload/v1783458499/omega-prod/Omega Cannabix Launch DOT Panel PR 07082026-04e4edc8-d81e-4e13-9979-144de5b0ccf2.pdf" target="_blank" rel="noopener">Download as a PDF</a> -- <a title="Visit omegalaboratories.com" href="https://www.omegalaboratories.com/" target="_blank" rel="noopener">Omega Laboratories, Inc. (Omega)</a>, and <a title="Visit Cannabix Technologies website for more information about Cannabix and their BCU" href="https://cannabixtechnologies.com/" target="_blank" rel="noopener">Cannabix Technologies Inc.</a> (CSE: BLO) (OTCID: BLOZF) announce the development and validation of a DOT-like drug-test panel for breath testing. The validated laboratory method expands Omega&rsquo;s breath-testing capability beyond cannabinoids and enables simultaneous detection of multiple drug classes in breath aerosols collected using Cannabix Technologies&rsquo; Breath Collection Unit (Figure 1).
<img style="display: block; margin-left: auto; margin-right: auto;" src="http://res.cloudinary.com/dnginndga/image/upload/v1783457999/omega-prod/BCU_in_hand-9bcf53d0-2104-455e-910c-6ef326b962fb.jpg" alt="Figure 1 - Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies." width="400" height="371" /> Figure 1 &ndash; Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.
The panel is modeled after the drug classes included in the DOT federally mandated urine drug test panel which includes amphetamines/methamphetamines, cocaine, marijuana, opiates and PCP. By validating these drug classes in breath, Omega is advancing a testing option designed to help employers, courts, criminal justice programs, treatment and recovery organizations, schools, and other safety-sensitive environments focus on recent drug use rather than historical use.
While marijuana legalization has accelerated demand for testing methods that can better distinguish recent use from historical use, safety-sensitive programs also need a practical way to determine whether drugs beyond marijuana are a concern. By expanding breath testing beyond cannabinoids to a broader DOT-like drug panel, Omega&rsquo;s method is designed to help decision-makers evaluate recent use across multiple drug classes in situations where timing, safety, and defensibility are critical.
Traditional drug testing matrices often identify use over longer detection windows. Oral fluid may detect use for one to two days, urine may detect certain drugs for several days, and hair may reflect drug use over a period of months. Breath testing is intended to address a more immediate window of detection, generally minutes to hours after use, making it particularly relevant for reasonable suspicion, random, post-incident, forensic, evidentiary, and other safety-sensitive testing scenarios.
&ldquo;This is an important milestone for breath testing and for organizations that need a more time-relevant tool for drug testing,&rdquo; said Bill Corl, CEO of Omega Laboratories. &ldquo;A DOT-like panel in breath gives customers a practical path to focus on recent use while maintaining the forensic quality, laboratory confirmation, and defensibility they expect from Omega.&rdquo;
Omega&rsquo;s laboratory-based breath testing is performed using mass spectrometry, a gold-standard analytical approach for confirming the presence of targeted analytes. The Cannabix Breath Collection Unit and Breath Cartridge system are designed to support observed, non-invasive collection and include safeguards such as a start-up airflow self-check, ambient air collection to help rule out environmental contamination, and split A/B sample collection to support confirmatory workflows.
Although many testing programs are interested in rapid onsite results, Omega&rsquo;s current breath test is intentionally laboratory-based to support the level of analytical sensitivity, confirmation, chain-of-custody integrity, and defensibility required in safety-sensitive, forensic, workplace, and criminal justice settings. The laboratory-based model allows breath testing to be positioned not as a presumptive screen, but as a scientifically supported recent-use testing option backed by mass spectrometry and Omega&rsquo;s established toxicology infrastructure.
The announcement builds on <a title="Read the peer-reviewed publication on THC Breath Testing in the Journal of Analytical Toxicology" href="/about-omega/news/omega-and-cannabix-announce-peer-reviewed-publication-on-thc-breath-testing-in-the-journal-of-analytical-toxicology">Omega&rsquo;s peer-reviewed work with Cannabix</a> in the Journal of Analytical Toxicology, which validated Omega&rsquo;s laboratory method for the simultaneous analysis of &Delta;9-THC, &Delta;8-THC, CBD, and CBN in breath aerosols collected using the Cannabix Technologies Breath Collection Unit. Together, the published cannabinoid validation and the expanded DOT-like panel validation reinforce Omega&rsquo;s commitment to developing reliable, defensible, and scientifically supported breath-testing solutions.
<a title="Learn more about Omega's current and expanding breath testing solutions" href="/testing/breath-testing">Omega&rsquo;s current THC breath test</a> and expanded DOT-like panel are available to existing and new clients. The company expects breath testing to be especially relevant in settings where decision-makers need to understand whether drug use was recent, while avoiding overreliance on testing methods that may primarily reflect past use. Omega believes laboratory-based breath testing may become an important complement to existing drug-testing matrices as employers and other safety-sensitive programs seek more time-relevant, scientifically defensible testing options.
Contact: For further information about Omega Laboratories, Inc., contact: Phone: <a title="Call Omega's client services for more information about Omega Laboratories" href="tel:800-665-5569">800-665-5569</a> Email: <a href="mailto:sales@omegalabs.net">sales@omegalabs.net</a>
For further information about Cannabix Technologies Inc., contact: <a href="mailto:info@cannabixtechnologies.com">info@cannabixtechnologies.com</a>
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often identified by terms such as &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;potential,&rdquo; &ldquo;proposed,&rdquo; &ldquo;positioned,&rdquo; and similar expressions, or statements that certain events or conditions &ldquo;may&rdquo; or &ldquo;will&rdquo; occur. Forward-looking statements in this release include, but are not limited to: statements regarding the development, validation, performance, capabilities, advantages, and potential use of breath-based drug-testing technologies; the potential application of a DOT-like multi-drug breath-testing panel for recent-use detection; the performance, capabilities, and advantages of the Cannabix Breath Collection Unit, Breath Cartridge, and related collection technologies; anticipated demand for laboratory-based breath testing; the scalability and manufacturing of devices and cartridges; the commercialization of technologies described; the potential adoption of breath testing by workplace, forensic, criminal justice, treatment and recovery, clinical, law enforcement, school, or other safety-sensitive customers; expectations regarding additional testing, pilot programs, regulatory processes, customer validation, or commercial deployments; and the growth of market opportunities related to recent-use drug testing. Forward-looking statements involve numerous risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the statements. Such risks include, but are not limited to: the risk that scientific results, including validation or peer-reviewed findings, may not be replicated in broader use; that further research, customer validation, or regulatory review may require changes to testing methods, device design, collection protocols, or reporting practices; risks associated with product development, manufacturing scale-up, supply chain availability, or cost escalation; risks relating to commercialization, customer adoption, and market acceptance of new testing technologies; the ability of the Company and its partners to meet regulatory, forensic, evidentiary, workplace, or other applicable standards; risks associated with intellectual property protection and patent approvals; competitive technologies or market changes; general economic, financial, or operational risks; and risks that expected agreements, partnerships, pilot programs, customer deployments, or commercial adoption may not materialize or may be delayed. There is no assurance that any proposed products or testing methods will be successfully developed, manufactured at scale, accepted by regulators or customers, or achieve commercial adoption. There is no assurance that breath-based drug testing, including THC or DOT-like multi-drug breath testing, will be accepted as a legal standard, workplace standard, or evidentiary tool in any jurisdiction, or that validation work or peer-reviewed publication will result in commercial, regulatory, or legal benefits. Actual results and future events may differ materially from those anticipated. All forward-looking statements in this release are made as of the date hereof and are based on current expectations, estimates, and assumptions that involve significant business, scientific, regulatory, and economic uncertainties. The Company undertakes no obligation to update forward-looking statements except as required by law.

Omega Laboratories and Cannabix Technologies announce the development and validation of a DOT-like drug-test panel for breath testing. 

Omega Laboratories and Cannabix Technologies Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection

<a title="Omega Laboratories Ranks #1 for Most Recognized Hair Testing Brand for the 5th year " href="http://res.cloudinary.com/dnginndga/image/upload/v1778853920/omega-prod/Omega%20NDASA%20Current%20Consulting%20Group%20survey%20results%202026%20Final-f4f1143d-b3cd-46e5-b0ec-592aeb0fbc1d.pdf">Download as PDF</a> -- We are thrilled to announce that Omega Laboratories has been ranked #1 for most recognized brand for hair testing for the fifth consecutive year!
Each year, Current Consulting Group announces the results of their annual survey of the employee screening industry at the National Drug and Alcohol Screening Association (NDASA) annual conference.
The survey includes questions on a variety of industry products and services such as laboratory analysis, collection site management, instant products and Medical Review Services. &nbsp;Industry experts rate providers on a variety of factors that determine which companies have the best brand recognition and quality.
It is a great honor to be recognized by our wonderful clients and partners in the industry. The positive feedback received highlights the quality of our testing services, and other important areas that matter most to our clients, such as
<ul class="branded">
<li>fast turnaround times</li>
<li>an easy sales process</li>
<li>quality project management</li>
<li>reliable client services</li>
<li>our full suite of technology offerings and data integration capabilities that help simplify your day-to-day business operations</li>
</ul>
Omega Laboratories is committed to delivering excellence in hair testing, as well as in our complete line of testing services. We strive to exceed your expectations in quality and ease of use for everyone who does business with us for years to come. Thank you for trusting us with your testing needs.
If you would like to learn more about Omega Laboratories&rsquo; hair testing services and why we continue to be recognized as a leader in the industry, call us at <a title="Call Omega Laboratories to learn more about our hair testing services" href="tel:330-628-5748">330-628-5748</a> or visit <a title="Learn more about Omega's hair testing services" href="/testing/hair-testing">hair testing services</a>.

We are thrilled to announce that Omega Laboratories has been ranked #1 for most recognized brand for hair testing for the fifth consecutive year!

News: Omega Laboratories Ranks #1 for Most Recognized Hair Testing Brand for the 5th year

MOGADORE, Ohio and VANCOUVER, BC, March 3, 2026 /PRNewswire/ -- <a title="Download a copy of the PDF - Journal of Analytical Toxicology Publishes Peer‑Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories' Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies' Breath Collection Unit" href="https://res.cloudinary.com/dnginndga/image/upload/v1774371443/omega-prod/Journal_of_Analytical_Toxicology_Publishes_Peer_Reviewed_Validation_Study_Demonstrating_Accuracy_of_Omega_Laboratories_Test_Method_for_Detecting_Marijuana_in_Breath_Samples_Using_Cannabix_Technologies_Breath_Collection_Unit_-_2026.pdf" target="_blank" rel="noopener">Download as a PDF</a> -- <a title="Visit omegalaboratories.com" href="https://www.omegalaboratories.com/" target="_blank" rel="noopener">Omega Laboratories, Inc. (Omega)</a>, and <a title="Visit Cannabix Technologies website for more information about Cannabix and their BCU" href="https://cannabixtechnologies.com/products/cannabix-marijuana-breath-test/" target="_blank" rel="noopener">Cannabix Technologies</a> Inc. (CSE: BLO) (OTCID: BLOZF) proudly announce the peer‑reviewed publication of a groundbreaking study published by Oxford University Press in the prestigious Journal of Analytical Toxicology titled: "Simultaneous Analysis of &Delta;9‑THC, &Delta;8‑THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit." This marks a major milestone in the advancement of marijuana breath testing technology globally.
<img src="http://res.cloudinary.com/dnginndga/image/upload/v1772551887/omega-prod/Cannabix-BCU-in-use-on-worksite-3f7a0460-5d15-456c-82f1-ee7637e60609.jpg" alt="Cannabix BCU in use at a worksite" width="300" height="287" align="right" />The study demonstrates the accuracy and utility of Omega Laboratories' analytical method for detecting cannabinoids in breath samples collected using Cannabix Technologies' Breath Collection Unit and Breath Cartridges&mdash;further validating the system as the leading solution for identifying recent marijuana use. For employers, law enforcement agencies, and safety‑sensitive industries, this breath‑based testing system offers a reliable, non‑invasive solution for detecting recent cannabis consumption. This capability fills a critical gap left by traditional methods, which often detect historical&mdash;rather than recent&mdash;use.
In May of 2024 Omega and Cannabix entered a strategic partnership to accelerate design improvements on the Cannabix Breath Collection Unit (BCU) as well as the laboratory test method. Over the course of 20 months, Cannabix made several key enhancements to the BCU while Omega refined the analytical methodology to <a title="Learn more about Omega Laboratories THC Breath Testing" href="https://www.omegalaboratories.com/testing/breath-testing" target="_blank" rel="noopener">test breath for usage of marijuana</a>. &nbsp;These successful efforts were combined into the validation study recently published by the Journal of Analytical Toxicology, which is available here: <a title="Read the full study published by the Journal of Analytical Toxicology" href="https://doi.org/10.1093/jat/bkag016" target="_blank" rel="noopener">https://doi.org/10.1093/jat/bkag016</a>
With medical and recreational marijuana use expanding, identification of recent cannabis use whether via smoking or ingestion has become more critical than ever for workplace drug testing, drug treatment facilities, and road safety programs. Detection of recent cannabis use in exhaled breath offers an alternative to the more invasive and intrusive testing methods using blood or urine. Breath testing, long established for alcohol detection, has recently gained attention for drug testing following evidence that multiple substances can be identified in breath after consumption. &nbsp;The detection window in breath correlates with those found in blood and can assist with the identification of recency of use within the last 4 hours prior to collection.
While alcohol breathalyzers are long-established, cannabis testing remains scientifically complex because THC levels in breath are extremely low. Omega has refined precision testing at these low levels for decades by being experts in utilizing <a title="Learn more about Omega Laboratories Hair Testing services" href="https://www.omegalaboratories.com/testing/hair-testing" target="_blank" rel="noopener">hair samples to detect long-term drug usage</a>. Omega's laboratory validated method combined with the Cannabix Breath Collection Unit has created the most commercially viable, non-invasive system for identifying same-day THC usage.
Publication in the Journal of Analytical Toxicology (JAT) indicates the research on the identification and measurement of toxic substances in biological samples has passed rigorous peer review. It adds to the body of knowledge for the toxicology community. JAT is the official journal of the Society of Forensic Toxicologists (SOFT) and The International Association of Forensic Toxicologists (TIAFT). The method was validated according to ANSI/ASB Standard 036, First Edition 2019 guidelines.
"This new publication reinforces the effectiveness of using breath to detect recent drug use," said Bill Corl, CEO of Omega. "This achievement further demonstrates our expertise in forensic toxicology and our commitment to providing advanced testing solutions."
Omega's method validation builds upon dozens of previously published papers while introducing several new key findings. &nbsp;These include:
<ol style="list-style: decimal; margin: 0 2rem 2rem 2rem;">
<li>The ability to simultaneously quantify multiple cannabinoids via breath aerosols including &Delta;9- tetrahydrocannabinol (&Delta;9-THC), &Delta;8-tetrahydrocannabinol (&Delta;8-THC), cannabidiol (CBD), and cannabinol (CBN).</li>
<li>The validation of a robust laboratory method that is quicker and simpler than previous approaches while achieving improved detection sensitivity and precision.</li>
<li>The establishment of breath sample stability for up to 7 days via the Cannabix Breath Collection Kit.</li>
<li>Further confirmation that the concentration versus time trends for THC metabolism assessed from breath correlate with those previously reported from blood.</li>
</ol>
Due to testing complexity requiring the use of LC-MS/MS, analysis must be performed in a laboratory. Collections performed at the roadside, workplace or in a clinic environment are sent to the laboratory and tested to see if a person had consumed marijuana 15 minutes to 4 hours prior to an incident. This is a very important tool that can be used in combination with other evidence for roadside and other safety sensitive investigations.
The <a title="Learn more about Omega Laboratories' breath testing process" href="https://www.omegalaboratories.com/testing/breath-testing" target="_blank" rel="noopener">breath collection process</a> includes an ambient air sample followed by an A &amp; B sample which are collected simultaneously with the use of the Cannabix collection cartridge. Omega screens the A sample using LC-MS/MS then, if presumptively positive, the B sample is also tested using LC-MS/MS. If both samples are positive the ambient air sample is tested to rule-out environmental contamination.
Rav Mlait, CEO of Cannabix Technologies, stated, "The peer‑reviewed article publication in the prestigious Journal of Analytical Toxicology is a significant milestone for Cannabix and its shareholders. I commend the dedicated efforts of both the Cannabix and Omega teams in advancing our breath-based technology to help improve public safety."
Cannabix is currently working to ramp up manufacturing of the BCU's and Breath Collection Kits. The Cannabix BCU brings several advantages:
<ol style="list-style: decimal; margin: 0 2rem 2rem 2rem;">
<li>Omega's validation helps establish the Cannabix BCU as a stable, consistent and portable tool for breath collection. &nbsp;The BCU offers a quick, non-invasive collection method regardless of subject's lung function.</li>
<li>The BCU adds several safeguards to the reproducible collection process, including the monitoring of subject's breath pressure and volume, the ability to collect ambient air for specimen validity, and A &amp; B cartridges for a dual testing process.</li>
<li>The Breath Collection Kit cartridges used by the BCU are currently the most robust method of sending breath samples for laboratory testing. The sturdy nature of the cartridges combined with shipping stability time helps ensure that samples can be successfully processed once received at Omega Laboratories.</li>
</ol>
The teams at Omega Laboratories and Cannabix are pleased to partner together so that this innovative, much-needed technology is available for safety-sensitive applications.
For additional information on these solutions, please contact Omega at <a title="Contact Omega Laboratories for additional information on these solutions" href="tel:1-800-665-5569" target="_blank" rel="noopener">1-800-665-5569</a> or <a title="Contact Omega Laboratories for additional information on these solutions" href="mailto:sales@omegalabs.net" target="_blank" rel="noopener">sales@omegalabs.net.</a>
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often identified by terms such as "anticipates," "expects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned," and similar expressions, or statements that certain events or conditions "may" or "will" occur. Forward‑looking statements in this release include, but are not limited to: statements regarding the interpretation, impact, and potential use of the peer‑reviewed study; the performance, capabilities, and advantages of the Cannabix Breath Collection Unit and Breath Collection Kits; anticipated demand for breath-based cannabis testing; the scalability and manufacturing of devices and cartridges; the development, validation, and commercialization of technologies described; the potential adoption of breath testing by workplace, forensic, clinical, or law enforcement customers; expectations regarding additional testing, pilot programs, or regulatory processes; and the growth of market opportunities related to cannabis impairment detection. Forward-looking statements involve numerous risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the statements. Such risks include, but are not limited to: the risk that scientific results, including validation or peer‑review findings, may not be replicated in broader use; that further research or regulatory review may require changes to testing methods or device design; risks associated with product development, manufacturing scale‑up, supply chain availability, or cost escalation; risks relating to commercialization, customer adoption, and market acceptance of new testing technologies; the ability of the Company and its partners to meet regulatory, forensic, or evidentiary standards; risks associated with intellectual property protection and patent approvals; competitive technologies or market changes; general economic, financial, or operational risks; and risks that expected agreements, partnerships, or deployments may not materialize or may be delayed. There is no assurance that any proposed products will be successfully developed, manufactured at scale, validated by regulators or customers, or achieve commercial adoption. There is no assurance that breath-based THC detection will be accepted as a legal standard or evidentiary tool in any jurisdiction, or that peer‑review publication will result in commercial, regulatory, or legal benefits. Actual results and future events may differ materially from those anticipated. All forward-looking statements in this release are made as of the date hereof and are based on current expectations, estimates, and assumptions that involve significant business, scientific, regulatory, and economic uncertainties. The Company undertakes no obligation to update forward‑looking statements except as required by law.

Omega Laboratories, a leading drug testing laboratory renowned for its comprehensive services, proudly announces the development and validation of a marijuana breath test. This validation includes a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix Technologies’ Breath Collection Unit (BCU). This establishes Omega and Cannabix as the premier technology for collecting and testing breath for recent marijuana usage. This method validation marks a significant milestone in the pursuit of innovative solutions for drug testing and safety assurance.

Omega and Cannabix announce peer-reviewed publication on THC Breath Testing in the Journal of Analytical Toxicology

MOGADORE, Ohio, Dec. 11, 2012 /PRNewswire/ -- Omega Laboratories, Inc. announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its Marijuana Metabolite Test, which detects the use of marijuana through human hair analysis. Omega Laboratories is one of the largest laboratories in the world performing hair testing for drugs of abuse and one of only three hair testing laboratories to have proven their capability to obtain FDA 510(k) clearances for the technology.
Omega has collaborated with Agilent Technologies to develop a highly-precise marijuana metabolite confirmation assay for the Agilent Technologies GC/MS/MS. This has enabled Omega to test at a Limit of Detection (LOD) level of 0.005 picograms per milligram of hair for the FDA submission. Additional research conducted by Omega Laboratories and Agilent Technologies has been presented at the Society of Forensic Toxicology (SOFT). This data confirms Omega's ability to reach an LOD as low as 0.002 picograms per milligram of hair for testing marijuana metabolite. "Over the last few years this collaboration with Omega has tested our GC/MS/MS product line in their production environment and we are very happy to report that the equipment maintained and continues to maintain the required precision," remarked Thomas Gluodenis, Forensics &amp; Toxicology Business Manager for Agilent Technologies.
The ability to test for Marijuana Metabolite has become increasingly important to organizations as drug abuse continues to increase and concerns grow about this serious and growing health problem. A recent report by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) identified marijuana as the most commonly abused form of illicit drug in the United States.
As stated at a meeting of the U.S. Department of Health and Human Service's Drug Testing Advisory Board (DTAB) in January 2011, the DTAB views this type of FDA clearance as a key component in the future adoption of hair testing for Federal Workplace Drug Testing Programs. In addition, many companies regulated by Federal Guidelines (such as the U.S. Department of Transportation's 49 CFR Part 40) have come to rely on hair testing for drugs of abuse because drug abuse has become a critical workplace safety issue. Regulated companies in industries such as trucking, oil and gas, nuclear power, and railroads, are now able to conduct expanded drug testing programs for safetysensitive positions under "company authority." These companies often do so because of the inherent flaws in the current urine-based Federal testing program.
"Omega prides itself on challenging the boundaries of what a hair testing laboratory can accomplish," said Bill Corl, CEO of Omega Laboratories. "Rather than confuse the market by patenting portions of these procedures, Omega has chosen to work with companies like Agilent Technologies to promote higher standards for the detection of drugs of abuse."
The Omega 510(k) submissions were evaluated by the FDA at a much more stringent level than those submissions cleared over a decade ago. Omega's 510(k) submissions averaged over 7,000 pages in length, and included extensive studies involving precision, agreement, stability, recovery, and possible effects of contamination. Omega also researched the possible effects of different hair cosmetic treatments including multiple coloring products, straighteners/relaxers, and shampoos specifically marketed to evade a drug test. Hair color, curvature, body location (head or body), and ethnic origin of the samples were analyzed to ensure that a diverse population was represented in the studies.
In addition to having clearance for Marijuana Metabolite testing, Omega has FDA clearance for Cocaine, Methamphetamine, PCP, Opiates and is currently the only hair testing laboratory to have FDA clearance for Codeine, Oxycodone, and Hydrocodone testing.

Omega has received 510(k) clearance from the Food and Drug Administration (FDA) for its Marijuana Metabolite Test, which detects the use of marijuana through human hair analysis. The Omega 510(k) submissions were evaluated by the FDA at a much more stringent level than those submissions cleared over a decade ago.

Omega Laboratories Receives FDA 510(k) Clearance for Hair-Based Marijuana Metabolite (THCA) Drug Test

MOGADORE, Ohio Jan. 13, 2026 /PRNewswire/ -- <a title="Download a copy of the PDF - Omega Laboratories Achieves the SAMHSA Accreditation for its online Custody and Control Form (oCCF) System" href="https://res.cloudinary.com/dnginndga/image/upload/v1768326021/omega-prod/Omega%20Laboratories%20Achieves%20the%20SAMHSA%20Accreditation%20for%20its%20online%20Custody%20and%20Control%20Form%20%28oCCF%29%20System%20-%202026-f8b39c0e-1646-4e5f-b8c9-c910221bc7a7.pdf" target="_blank" rel="noopener">Download as a PDF</a> -- Omega Laboratories, Inc. (Omega), a leading provider of comprehensive drug testing solutions, announces that its state-of-the-art online Custody and Control Form System (oCCF) has received the Substance Abuse and Mental Health Services Administration (SAMHSA) accreditation from the National Laboratory Certification Program (NLCP) for its electronic custody and control form system to collect samples for Federally Regulated Drug Testing Programs. This prestigious accreditation solidifies Omega's commitment to lead the industry in technology, quality, accuracy, and integrity in drug testing. Now clients that fall under the Federally Regulated Drug Testing Programs will have a more convenient method to generate a custody and control form for a drug test collection at <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4594088-1&amp;h=3225763250&amp;u=http%3A%2F%2Fwww.occf.com%2F&amp;a=www.occf.com" target="_blank" rel="nofollow noopener">www.occf.com</a>.
SAMHSA's rigorous evaluation process ensures that only a select group of qualified laboratories, meeting or exceeding the industry's highest requirements, can be accredited to this esteemed program. Omega is currently the only laboratory in North America to have an online custody and control form system in 16 languages. In addition to SAMHSA urine testing, Omega's oCCF can be utilized to collect non-regulated testing including urine, oral fluid, hair, breath and any type of POCT device or configuration. This status underscores Omega's exceptional commitment to excellence and positions Omega among the most distinguished in the field.
"We are proud to achieve the SAMHSA accreditation for our oCCF system," said Jerry Crosby, President of Omega. "This achievement further demonstrates our expertise in forensic toxicology, but also our commitment to making collections and testing easier for collectors, clinics and clients.&nbsp; The flexibility of the oCCF system to be used with or without wifi, makes it the perfect application for any type of collection, anywhere or anytime a collection is being performed."
The SAMHSA accreditation positions Omega as a trusted partner for collectors, clinics and businesses looking for a complete drug screening solution. Omega has over 25 years of experience with advanced specimens such as oral fluid, hair and breath. Having the SAMHSA credential for our Omega Ontario laboratory to use our oCCF for urine testing will enable Omega to quickly add oral fluid, hair and breath to its SAMHSA accredited test menu once the matrices are approved by HHS.
The importance of the SAMHSA accreditation extends beyond the validation of Omega's technical proficiency and compliance. It also brings Omega's excellent client service, industry-leading turnaround time and technology solutions to the federally regulated drug testing market. With this accreditation, Omega is well-positioned to cater to a wider range of clientele, including government agencies, law enforcement organizations, and workplace programs. SAMHSA accreditation is required to test for key safety-sensitive candidates such as those employed under the Department of Transportation (FMCSA, FAA, FRA), energy (PHMSA, NRC), and armed services (DoD, DHS/USCG). This type of testing contributes to public safety in communities by keeping roadways and other forms of transportation safe.
As the US Drug Testing regulations expand beyond the US borders and Territories, the oCCF's multi-language capabilities ensure that proper collection procedures are followed and that a donor understands what they are consenting to for testing and what information is being captured for the collection.&nbsp;
For additional information on these solutions, please contact Omega at 1-800-665-5569 or&nbsp;<a href="mailto:sales@omegalabs.net" target="_blank" rel="nofollow noopener">sales@omegalabs.net</a>&nbsp;
About Omega Laboratories, Inc.&nbsp;&ndash; Omega Laboratories, headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 25 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody &amp; Control Form system (oCCF) in sixteen languages, Software as a Service (SaaS) of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers laboratories in countries that have demand for local service providers.&nbsp;<a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4594088-1&amp;h=138859959&amp;u=http%3A%2F%2Fwww.omegalaboratories.com%2F&amp;a=www.omegalaboratories.com" target="_blank" rel="nofollow noopener">www.omegalaboratories.com</a>

Omega Laboratories, Inc. (Omega), a leading provider of comprehensive drug testing solutions, announces that its state-of-the-art online Custody and Control Form System (oCCF) has received the Substance Abuse and Mental Health Services Administration (SAMHSA) accreditation from the National Laboratory Certification Program (NLCP) for its electronic custody and control form system to collect samples for Federally Regulated Drug Testing Programs.

Omega Laboratories Achieves the SAMHSA Accreditation for its online Custody and Control Form (oCCF) System

MOGADORE, Ohio, March 18, 2025 /PRNewswire/ -- <a title="Download a PDF of this press release" href="http://res.cloudinary.com/dnginndga/image/upload/v1742303561/omega-prod/Omega Laboratories Completes Method Validation With Cannabix Technologies Inc 03_2025_Final-39e1d503-ae89-43ad-a41d-526fc1c81f93.pdf" target="_blank" rel="noopener">Download as PDF</a> -- Omega Laboratories, a leading drug testing laboratory renowned for its comprehensive services, proudly announces the development and validation of a marijuana breath test. This validation includes a test method for the simultaneous quantification of &Delta;-9-tetrahydrocannabinol (THC), &Delta;-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix Technologies&rsquo; Breath Collection Unit (BCU). This establishes Omega and Cannabix as the premier technology for collecting and testing breath for recent marijuana usage. This method validation marks a significant milestone in the pursuit of innovative solutions for drug testing and safety assurance.
Cannabix Technologies Inc. and Omega have collaborated to optimize the design of the Cannabix BCU and compact Breath Cartridge technology. &nbsp;The BCU includes a start-up unit air flow self-check, the ability to collect an ambient air sample to rule out external contamination from the immediate surrounding area, a split sample configured Breath Cartridge to simultaneously collect an A and B sample, and a collection system that will stop drawing in air should the donor stop breathing into the device. This prevents the device from pulling in ambient air from the surrounding area and a donor from trying to cheat the collection. The Cannabix BCU is at the forefront of advanced breath collection tools to collect breath accurately and non-invasively.
Omega Laboratories is currently in the process of incorporating breath testing into its suite of services. With credible and extensive research backing Cannabix's technology, including validation studies demonstrating its efficacy, Omega Laboratories is confident in the reliability and accuracy of the THC breath test system. In partnership with Cannabix, Omega has completed a full validation study that will be published to further demonstrate the effectiveness of the breath testing system in real-world testing scenarios.&nbsp; This will ensure unparalleled accuracy and reliability for clients.
"At Cannabix Technologies, we are thrilled with the method validation results from Omega Laboratories, a company that upholds a tradition of excellence in drug testing, backed by their extensive accreditations and certifications,", stated, Rav Mlait, CEO of Cannabix Technologies Inc. "This partnership success further solidifies our commitment to providing trusted and highly accredited solutions, offering unparalleled expertise and reliability to future clients."
The integration of Cannabix's THC BCU technology with Omega Laboratories' testing protocols will enable rapid and precise detec&shy;&shy;tion of THC levels in breath samples. This innovative approach not only streamlines the testing process but also ensures reliable results for clients across various industries, including law enforcement, workplace safety, and healthcare.
Furthermore, as part of this collaboration, all breath samples analyzed by Omega Laboratories undergo a testing process using mass spectrometry (mass spec), a gold standard in analytical chemistry to confirm which analytes are present. This meticulous approach reinforces Omega's commitment to maintaining the highest forensic standards of quality and integrity.
With the rise in cannabis legalization, employers face new challenges in detecting recent use of marijuana. Traditional cannabis testing methods, such as oral fluid, urine, and hair tests, can detect cannabis use for extended periods, ranging from days to months. The premier solution for recent use detection will be utilizing the Cannabix BCU to collect breath then sending the sample to Omega for analysis. Omega will then detect if there was recent THC usage (minutes to several hours).
"Our partnership with Cannabix Technologies underscores our commitment to staying at the forefront of advancements in drug testing technology," said Bill Corl, CEO of Omega Laboratories. "By incorporating their groundbreaking THC breath collection technology, we are poised to enhance the accuracy, efficiency, and accessibility of cannabis testing."
For additional information on these solutions, please contact Omega at <a title="Call Omega Laboratories for additional information on breath testing solutions and more" href="tel:1-800-665-5569">1-800-665-5569</a> or <a title="Email Omega Laboratories for additional information on breath testing solutions and more" href="mailto:sales@omegalabs.net">sales@omegalabs.net</a>.

Omega Laboratories Completes Method Validation with Cannabix Technologies Inc. for Marijuana Breath Detection

MOGADORE, Ohio, May 16, 2024 /PRNewswire/ -- Omega Laboratories, a leading drug testing laboratory renowned for its comprehensive services, proudly announces its strategic partnership with Cannabix Technologies Inc., a pioneer in cannabis breathalyzer technology. This partnership establishes Omega as the exclusive provider of laboratory services. This collaboration marks a significant milestone in the pursuit of innovative solutions for drug testing and safety assurance.
Cannabix Technologies Inc. is at the forefront of developing advanced breath analysis tools to detect THC levels accurately and non-invasively. Leveraging their expertise and cutting-edge technology, Omega Laboratories aims to revolutionize the landscape of drug testing by integrating Cannabix's THC breathalyzer into its suite of services. With credible and extensive research backing Cannabix's technology, including validation studies demonstrating its efficacy, Omega Laboratories is confident in the reliability and accuracy of the THC breathalyzer. In partnership with Cannabix, Omega will be performing a full validation study to further demonstrate the effectiveness of the breathalyzer technology in real-world testing scenarios, ensuring unparalleled accuracy and reliability for clients.
"At Cannabix Technologies, we are thrilled to partner with Omega Laboratories, a company that upholds a tradition of excellence in drug testing, backed by their extensive accreditations and certifications,", stated, Rav Mlait, CEO of Cannabix Technologies Inc. "This partnership further solidifies our commitment to providing trusted and highly accredited solutions, offering unparalleled expertise and reliability to our clients."
The integration of Cannabix's THC breathalyzer technology into Omega Laboratories' testing protocols will enable rapid and precise detec&shy;&shy;tion of THC levels in breath samples. This innovative approach not only streamlines the testing process but also ensures reliable results for clients across various industries, including law enforcement, workplace safety, and healthcare.
Furthermore, as part of this collaboration, all breathalyzer samples analyzed by Omega Laboratories will undergo rigorous testing using mass spectrometry (mass spec), a gold standard in analytical chemistry. This meticulous approach reinforces Omega's commitment to delivering accurate and reliable results, maintaining the highest standards of quality and integrity.
With the rise in cannabis legalization, employers face new challenges. Traditional cannabis testing methods, such as oral fluid, urine, and hair tests, can detect cannabis use for extended periods, ranging from days to months. However, utilizing the Cannabix breathalyzer to test breath for cannabis isolates THC detection to just a few hours after use.
"Our partnership with Cannabix Technologies underscores our commitment to staying at the forefront of advancements in drug testing technology," said Bill Corl, CEO of Omega Laboratories. "By incorporating their groundbreaking THC breathalyzer technology, we are poised to enhance the accuracy, efficiency, and accessibility of cannabis testing."
With this strategic partnership, Omega Laboratories and Cannabix Technologies are poised to drive innovation and set new standards in cannabis testing, ensuring safer communities and workplaces.
For additional information on these solutions, please contact Omega at 1-800-665-5569 or&nbsp;sales@omegalabs.net.
&nbsp;
Cannabix News Updates:
July 11, 2024 - <a href="https://cannabixtechnologies.com/investors/news-releases/cannabix-technologies-and-omega-laboratories-inc-provide-positive-developments-on-marijuana-breathalyzer-testing/">Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer&nbsp;Testing</a>

Omega Labs partners with Cannabix Technologies to enhance drug testing capabilities, offering advanced solutions for accurate detection of cannabis use.

Omega Laboratories Partners with Cannabix Technologies Inc. for Marijuana Breath Detection

Omega Laboratories is honored to have participated in a meeting organized by the Institute for Safe Traffic Technologies&nbsp; and the Brazilian mission hosted at the United Nations in New York to discuss the rapidly growing success of hair drug testing in Brazil. This meeting, which included the presentation of both Brazilian and US statistics, demonstrated the impressive capabilities of hair testing for drugs of abuse, especially in the transportation industry.&nbsp; This event was attended by a large number of transportation and drug testing industry experts, including Brazil&rsquo;s former President Fernando Henrique Cardoso&cedil; Director of the National Department of Transit (DENATRAN) Maur&iacute;cio Alves. Two years ago, Brazil implemented a law that required professional drivers pass a hair drug test before receiving or renewing their commercial licenses. According to the Brazilian Federal Highway Police, this change &ldquo;contributed to a 38% drop in the number of fatal accidents involving trucks on Brazilian federal highways in just the first six months of the requirement.&rdquo; Furthermore, the data shows that the implementation of this program has also dissuaded a large number of drug users from applying for C, D and E class licenses.&nbsp; &nbsp;The former President of Brasil addressed the importance of hair testing, stating "We must continue to move forward in this process of modernization. What we are seeing is the implementation of a policy based on technological advances that ensure the public's health and safety." Omega Laboratories is honored that their Brazilian testing data&nbsp; was discussed during the presentations and is confident that this continued success for hair testing will lead companies, industries, and countries to recognize and choose hair testing as the superior drug testing method.&nbsp;

Omega Laboratories is honored to have participated in a meeting organized by the Institute for Safe Traffic Technologies  and the Brazilian mission hosted at the United Nations in New York to discuss the rapidly growing success of hair drug testing in Brazil.

Omega Laboratories Attends United Nations Meeting on Hair Drug Testing

MOGADORE, Ohio, May 15, 2018 /PRNewswire/ -- Omega Laboratories is proud to introduce the Omega Hair 17-panel drug test, the most comprehensive hair test ever offered. This new offering tests for 45 different substances, helping safety-sensitive employers to proactively address the growing epidemic of hard drug use around the globe. This exciting new panel, which will be available starting on June 4th, 2018, will offer the detection of a much wider class of drugs of abuse, including Benzodiazepines, Barbiturates, Fentanyl, Tramadol and Ketamine.
Omega's new Hair 17-panel is the largest hair test on the market to utilize proven ELISA screening technology, developed from the same process for which Omega has been granted a number of 510(k) clearances from the U.S. Food and Drug Administration (FDA). This means that employers, government agencies and other entities can now expand their drug testing programs while still benefitting from the assurance provided by Omega's industry-leading credentials.&nbsp;
This new panel offers testing for a total of 45 different substances, including 8 commonly abused variants of Benzodiazepines. The test has been specifically designed to address the current growing trends in workplace drug abuse, including the rise of Fentanyl and prescription opiate abuse as well as the introduction of Ketamine from outside of&nbsp;the United States.
"Hair testing is a lifestyle test, showing an approximate 90-day window of usage," said&nbsp;Bill Corl, Omega's CEO. "This makes hair testing the perfect tool to identify if someone is at risk of becoming another statistic in this growing epidemic."
This new panel uses a proprietary screening method which allows Omega to screen for 17+ drug classes using only 12.5 mg of hair. This new method helps Omega to maintain their reputation as the most innovative forensic hair testing laboratory. Like all of Omega's proven hair testing, confirmations are performed using Mass Spectrometry methods, such as GC/MS/MS, and LC/MS/MS technology.
"This is not the first time Omega has chosen to innovate ahead of our competitors," said&nbsp;John Vitullo, Omega's Chairman. "We understand that the needs of the global drug testing markets are continually changing and we are here to lead that advancement."
The drugs included in the screen are Amphetamines, Methamphetamines, Cocaine, Marijuana, Opiates, Synthetic Opiates, Fentanyl, PCP, Benzodiazepines, Barbiturates, Methadone, Propoxyphene, Meperidine, Tramadol, Ketamine, Buprenorphine and Zolpidem. For additional information and cutoff levels, please contact Omega at 1-800-655-5569 or&nbsp;<a href="mailto:sales@omegalabs.net" target="_blank" rel="nofollow noopener">sales@omegalabs.net</a>.

Omega Laboratories is proud to introduce the Omega Hair 17-panel drug test, the most comprehensive hair test ever offered. This new offering tests for 45 different substances, helping safety-sensitive employers to proactively address the growing epidemic of hard drug use around the globe.

Omega Laboratories Announces Groundbreaking 17-panel Hair Drug Test to Help Organizations Tackle Drug Epidemic

MOGADORE, Ohio,&nbsp;Oct. 4, 2022&nbsp;/PRNewswire/ -- Omega Laboratories ("Omega"), a leading provider of laboratory testing solutions, announced the acquisition of Acumium, a leading technology and software development firm. This partnership further enhances Omega's ability to provide the highest level of risk mitigation while also providing more timely results for faster clinical, court and employment decisions.

Acumium is a&nbsp;Madison, WI&nbsp;based information technology firm with over 21 years of experience specializing in software development, data privacy &amp; protection, cloud computing, and managed IT services. Acumium's primary goal is to develop and tailor technology solutions that solve problems.
Omega Technology Solutions' suite of tools currently includes the oCCF (Online Custody &amp; Control Form), data integration capabilities, secure reporting services, Medical Review Officer Module, and LIMS (Laboratory Information Management Systems). These products are already in use by multinational organizations that need to meet stringent regional data and accreditation standards.
Omega has long been the leader in quality laboratory testing solutions with fast turnaround times. Omega has worked with Acumium for over 15 years to create applications that facilitate accuracy, data security and data privacy from the initial collection request through laboratory processing to result reporting and statistical analysis. These applications have become a core part of Omega's full laboratory solutions. Omega acquired Acumium to merge the industry's best laboratory team with the most advanced technology solutions team. Omega can now continue to refine these systems, which will improve every step of the testing process for our clients. Some of these solutions are already being used by other firms through license or under a Software as a Service (SaaS) agreements. The Acumium Team will easily be able to support and promote the long-standing Omega solutions with their long-standing software solutions portfolio.
"The oCCF system is an example of a successful collaboration between Omega and Acumium in recent years," said&nbsp;Bill Corl, Omega's CEO. "This system is available in multiple languages, can be utilized on a tablet or a desktop, and manages both laboratory-based testing and point of collection testing."
For additional information on these solutions, please contact Omega at 1-800-655-5569 or&nbsp;<a href="mailto:sales@omegalabs.net" target="_blank" rel="nofollow noopener">sales@omegalabs.net</a>.

Omega Laboratories ("Omega"), a leading provider of laboratory testing solutions, announced the acquisition of Acumium, a leading technology and software development firm. This partnership further enhances Omega's ability to provide the highest level of risk mitigation while also providing more timely results for faster clinical, court and employment decisions.

Omega Laboratories Acquires Acumium to form Omega Technology Solutions

CLEVELAND, Ohio, USA,&nbsp;Aug. 4, 2014&nbsp;/PRNewswire/ --&nbsp;Omega Laboratories, Inc. unveiled their newly completed laboratory expansion today, a project undertaken in response to the increasing global demand for testing drugs of abuse in hair.&nbsp;With an investment of&nbsp;5 million USD, Omega's US-based headquarters now consists of over 44,000 square feet which quadruples Omega's daily testing capacity. The new addition has been outfitted with state of the art mass spectrometry equipment and staffed by Omega's highly experienced personnel.
Omega attributes its impressive growth to many factors, including having the fastest testing turnaround time in the industry, consistently reporting results within 24-72 hours while maintaining a high level of accuracy. The turnaround time is a result of proprietary testing methods, part of the intellectual property and operating efficiencies developed by Omega over the last 14 years. This includes a specimen wash process which has been approved by multiple accrediting agencies as an effective means for removing external contamination. Omega is one of only three hair testing laboratories worldwide to have obtained FDA 510(k) clearances.
Omega has also earned a respected position within the global scientific community by providing consistent fact-based assistance and supporting the standardization for hair testing globally. The United Nations Office on Drugs and Crime recently sought Omega's expertise in reviewing the latest&nbsp;Guidelines for Testing Drugs under International Control in Hair, Sweat and Oral Fluid. This respected position has been earned, as Omega has spent years participating in meetings with government agencies, political advisors, and decision-making committees, including over forty meetings with members of the United States Congress. Because of these efforts, Omega has become the preferred expert in regulatory affairs.
Omega's hair and oral fluid testing offer numerous benefits over urine testing for clients worldwide, including identifying more drug users, tests that are harder to evade, and samples which are easier to collect and ship.
About Omega Laboratories, Inc. - Omega is a state-of-the-art laboratory providing hair and oral fluid testing for drugs of abuse to over 6,000 clients worldwide. Omega is accredited to ISO/IEC 17025 standards through Forensic Quality Services (FQS), holds a College of American Pathologists (CAP) Accreditation for Forensic Drug Testing, and 510(k) clearances from the FDA. Omega's reputation for performing accurate, timely and cost effective testing, coupled with a reputation for outstanding client service, has positioned Omega as the leader in hair drug testing.

Omega Laboratories, Inc. unveiled their newly completed laboratory expansion today, a project undertaken in response to the increasing global demand for testing drugs of abuse in hair. With an investment of 5 million USD, Omega's US-based headquarters now consists of over 44,000 square feet which quadruples Omega's daily testing capacity.

Omega Laboratories Quadruples Hair Drug Testing Capabilities

MOGADORE, Ohio, June 13, 2012 /PRNewswire/ -- Omega Laboratories, Inc. recognizes and applauds yesterday's announcement that the remaining laboratory of those accredited by the College of American Pathologists (CAP) for forensic hair drug testing has decided to utilize Enzyme Immunoassay technology. This announcement comes after a decade of disagreement and confusion regarding differing methodologies and proprietary techniques. This change could signal that the hair testing industry has finally come to a consensus on the superiority of Enzyme Immunoassay technology as a screening method for drugs of abuse.
This announcement represents a unity of methodology within the hair testing industry, as all three major workplace hair testing laboratories now use EIA as their screening method of choice. Omega anticipates that this harmonization on screening methodologies will aid in the acceptance of hair testing by the Substance Abuse and Mental Health Services Administration (SAMHSA) and their Drug Testing Advisory Board (DTAB).
Omega Laboratories has chosen to use Enzyme Immunoassay (EIA) technology since its inception in 2000, citing superior accuracy, reliability, and low impact upon the environment. Omega's use of EIA for 12 years has contributed to its position as a leader in the hair testing industry, allowing Omega to be an active and successful participant in worldwide proficiency testing programs. In addition, it has aided Omega in securing prestigious international accreditations and Food and Drug Administration (FDA) clearances for the company's screening assays.
Enzyme Immunoassay (EIA) is a quick and cost effective biochemistry assay used to identify the presence of substances within specimens. When used for drugs of abuse screening, this technology allows laboratories to efficiently and accurately detect drugs of abuse in hair specimens, which can then be confirmed through GC/MS and LC/MS technology. Since the 1992 publication of a World Health Organization study, which highlights the benefits of EIA technology, EIA has become the prevailing method of choice worldwide.
A common predecessor of EIA is Radioimmunoassay (RIA), which uses radioactive signal to detect substances within a sample. Some members of the hair testing for drugs of abuse industry have continued to market the use of RIA technology, despite widespread knowledge that this practice creates radioactive waste, which raises environmental concerns.
"It is exciting to hear that another laboratory has joined Omega in using Enzyme Immunoassay technology," said Dr. John Vitullo, CEO of Omega Laboratories. "We have used this technology at Omega for over 12 years with great success and we know that the adoption of EIA by our competitors will not only be better for the environment, but will also help to establish equivalence and convergence in hair testing results across different laboratories."
In addition to numerous international accreditations, Omega Laboratories has utilized EIA to receive FDA screening assay clearances for its Cocaine, Methamphetamine, PCP, and Opiates panels, and is the only hair testing laboratory to have documented clearance for Codeine, Oxycodone and Hydrocodone testing.

Omega Laboratories, Inc. recognizes and applauds yesterday's announcement that the remaining laboratory of those accredited by the College of American Pathologists (CAP) for forensic hair drug testing has decided to utilize Enzyme Immunoassay technology. This announcement comes after a decade of disagreement and confusion regarding differing methodologies and proprietary techniques. This change could signal that the hair testing industry has finally come to a consensus on the superiority of Enzyme Immunoassay technology as a screening method for drugs of abuse.

Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories

SALT LAKE CITY, April 26, 2011 /PRNewswire/ -- C.R. England, a Salt Lake City-based global transportation provider, and Omega Laboratories, Inc. a state-of-the art drug testing facility, have announced an innovative drug screening partnership that will test the hair samples of driver applicants. This program will enhance England's preemployment drug screening process with the end result of putting safer drivers on the road.
"The industry-wide impact of being able to conduct a pre-employment drug test that reviews a longer screening history is a tremendous improvement over the current Federally mandated requirements," said Dustin England, Vice President of Safety and Compliance for C.R. England. "With hair testing, we are able to detect months of time rather than the handful of days checked with standard urine tests. We found our hair testing positive rate was over three times higher than the required DOT urine test alone."
During the trial, both urine and hair samples were collected. After a year of research, the management team at C.R. England became convinced that hair testing was a superior methodology for pre-employment drug screening and offered a much more effective screening process than urine testing. England will continue to conduct standard urine drug testing for all applicants as required by the DOT.
Results of the trial program clearly show its effectiveness. Out of 2,000 candidates, over 150 tested positive that would have otherwise passed the current Federally-mandated testing. In total, over 11 percent tested positive with hair resting, versus 2.8 percent testing positive with DOT urine testing.
In addition to being a leader in the refrigerated trucking industry, C.R. England operates four driving schools across the United States. "By operating our own schools, we can provide the best training for our future professional truck drivers and their safety," England says. "By hair testing we can better control the quality of successful applicants. Knowing we can keep more potentially dangerous drivers off the roads is a great feeling," continues England. "That is why we are now firm believers in the benefits of hair testing for the transportation industry."
About C.R. England, Inc.: Founded in 1920 with corporate headquarters in Salt Lake City, C.R. England, Inc. is one of North America's largest transportation companies and the world's largest temperature-controlled carrier. C.R. England services include National, Mexico and Regional Truckload service in addition to Dedicated and Intermodal services. Additional services include Leasing, Brokerage, LTL/Parcel, Supply Chain Engineering, Special Project Engineering, Warehousing, and Global Sourcing, which includes offices in Southern California and China. For more information, visit <a title="Learn more about C.R. England" href="https://www.crengland.com/" target="_blank" rel="noopener">www.crengland.com</a>.

C.R. England, a Salt Lake City-based global transportation provider, and Omega Laboratories, Inc. a state-of-the art drug testing facility, have announced an innovative drug screening partnership that will test the hair samples of driver applicants. This program will enhance England's preemployment drug screening process with the end result of putting safer drivers on the road.

C.R. England Improves Safety With Innovative Approach to Applicant Screening

MOGADORE, Ohio, July 23, 2013 /PRNewswire/ -- Omega Laboratories, Inc. is pleased to announce that it is assisting the Drug Testing Advisory Board (DTAB) with the evaluation of hair specimens for use in the Federal Workplace Drug Testing Program. Recent concerns and data have emerged which challenge the effectiveness of traditional urine-based testing. As a result, the DTAB assembled authorities from across the drugs of abuse testing industry, including Omega's Laboratory Director Dr. David Engelhart, at its July meeting in order to thoroughly explore the testing of hair specimens as a valuable and long-needed addition to the Federal Workplace Drug Testing Program.
During the July 15th DTAB meeting in Rockville, Maryland, members were given presentations by highly-recognized authorities in the drug testing industry, including the laboratory directors from the three largest United States based workplace hair testing laboratories. Dr. David Engelhart of Omega Laboratories confirmed the proven scientific reproducibility of hair testing, stating that "proficiency testing has shown consistent results of the hair testing screening processes across multiple laboratories worldwide."
Public comments at this meeting mirrored those from other DTAB meetings over the last several years, which strongly favored the addition of hair as a specimen for testing. Five-years of dual testing data from the trucking industry, which included over 200,000 DOT driver candidates from more than 25 different motor carriers, demonstrates that urine testing by itself is no longer effective for pre-employment screening. Industry experts in attendance noted the availability of existing qualifications for testing laboratories, including accreditation by the College of American Pathologists (CAP) and the internationally accepted ISO/IEC 17025 standard, as well as the thorough review and clearances already granted by the Food and Drug Administration (FDA), another agency within Health and Human Services (HHS). The fact that the three main workplace hair testing laboratories have achieved equivalent levels of accreditation and participate in a robust international proficiency testing program should lead to swift and simple acceptance.
Since 1988, organizations that are required to perform Federal Workplace Drug Testing have been limited to the use of urine specimens. Many motor carriers have chosen to go above and beyond the federal requirements and have added hair testing to ensure that they are screening out potentially dangerous employees. This comes at a cost, as these companies are still required to pay for the currently mandated urine testing as well. Hair specimen testing provides a significantly longer detection window, is very difficult to adulterate, and eliminates collection issues associated with urine. As a result, hair testing has consistently identified over three times as many illegal substance users as urine testing in regulated industry pre-employment trial programs. Regulated industries in other countries, including airlines and government agencies, have already had improved success with both hair and laboratory-based oral fluid testing.
The DTAB is an advisory committee for the Substance Abuse and Mental Health Services Administration (SAMHSA), who established the board to "improve the quality of systems for drug testing." The decision to evaluate hair testing comes only eighteen months after the DTAB fast-tracked the review of laboratory-based oral fluid testing which also offers many advantages over traditional testing methods.
"We feel that the acceptance of both hair and laboratory-based oral fluid testing by SAMHSA will be a key factor in maintaining the United States drug testing program's position as the true 'gold standard,'" states Bill Corl, CEO of Omega Laboratories.
About Omega Laboratories, Inc. - Omega Laboratories, Inc. is a state-of-the-art facility providing laboratory-based hair and oral fluid testing for drugs of abuse to over 5,000 clients worldwide. Omega currently holds CAP Forensic Drug Testing accreditation, is accredited to ISO/IEC 17025 standards, and has obtained screening clearances from the FDA. Omega's reputation for performing accurate, timely and cost effective testing, coupled with an unmatched reputation for client service, has positioned Omega as the leader in the alternative specimen drug testing industry.

Omega Laboratories, Inc. is pleased to announce that it is assisting the Drug Testing Advisory Board (DTAB) with the evaluation of hair specimens for use in the Federal Workplace Drug Testing Program. Recent concerns and data have emerged which challenge the effectiveness of traditional urine-based testing. As a result, the DTAB assembled authorities from across the drugs of abuse testing industry, including Omega's Laboratory Director Dr. David Engelhart, at its July meeting in order to thoroughly explore the testing of hair specimens as a valuable and long-needed addition to the Federal Workplace Drug Testing Program. 

Omega Laboratories Presents Data on Hair Specimens for Federal Workplace Drug Testing Program

PACIFIC, Wash.,&nbsp;Sept. 20, 2011&nbsp;/PRNewswire/ -- Gordon Trucking, one of the nation's most reliable truckload carriers, has begun drug screening all applicants via hair samples with the goal of reducing new driver accidents within the first crucial months of employment. &nbsp;Gordon joins a growing list of carriers that perform hair testing under company authority to supplement the minimum DOT mandated urine testing requirements. &nbsp;
"Research has shown most accidents occur within the first 90-120 days of employment," states&nbsp;Scott Manthey, Vice President of Safety and Compliance for Gordon Trucking. &nbsp;"Once a driver makes it through that initial period the risk of an accident drops dramatically. &nbsp;We feel that a urine test combined with the longer timeframe of a hair test offers one the best possible screening tools. We have concluded that this aids in selecting some of the safest and most professional drivers on the road."
The program started in&nbsp;July 2011&nbsp;with Omega Laboratories, Inc. and has already shown beneficial results. &nbsp;Of the 170 drivers already screened, hair testing has detected 10 positive candidates that would have otherwise been hired. &nbsp;"Beyond the candidates who have tested positive," adds Manthey, "we also routinely have candidates dismiss themselves from orientation classes once they confirm a hair test will be conducted." &nbsp;
Safety-conscious carriers like Gordon Trucking not only follow minimum federal requirements, but often choose to utilize new advances in technology. &nbsp;Once such innovations are proven to be effective, they are often incorporated into future federal policy. &nbsp;Hair testing is just one example of motor carriers raising the bar on safety. &nbsp;Other examples of optional policies under company authority currently include drug testing for extended opiates, use of Electronic On-Board Data Recorders, and sleep apnea screening.
"After considerable research, Gordon Trucking concluded that it was our responsibility to raise the bar for driver screening ," states Manthey. &nbsp;
"While the spread of dual DOT urine and hair testing programs is encouraging, additional reforms need to be implemented as well. &nbsp;The proposals for a 'Drug Test Clearinghouse' should be expanded to include any drug or alcohol screen that has been medically reviewed, not just those tests mandated by the DOT," asserts Manthey. &nbsp;"Additional training should also be stipulated for all Medical Review Officers and physicians involved in the screening process."
"Professional, responsible drivers are a carrier's best asset," summarizes Manthey. &nbsp;"Removing controlled substance abusers from the commercial motor vehicle is a critical part of improving the safety of America's highways. "
About Gordon Trucking Inc.:&nbsp;&nbsp;With over&nbsp;2500 employees and 1900 trucks, Gordon Trucking is the 22nd largest truckload carrier in&nbsp;North America&nbsp;and the 64th largest for-hire carrier overall. &nbsp;Gordon Trucking offers local, regional and trans-continental truckload services within&nbsp;the United States&nbsp;and to and from&nbsp;Canada&nbsp;including temperature control and regional heavy haul service. &nbsp;For more information, visit&nbsp;<a title="Learn more about Gordon Trucking Inc" href="http://www.gordontrucking.com/" target="_blank" rel="noopener">www.gordontrucking.com</a>.

Gordon Trucking, one of the nation’s most reliable truckload carriers, has begun drug screening all applicants via hair samples with the goal of reducing new driver accidents within the first crucial months of employment.  Gordon joins a growing list of carriers that perform hair testing under company authority to supplement the minimum DOT mandated urine testing requirements.  

Gordon Trucking Implements Hair Testing With Goal of Reducing New Driver Accidents

MOGADORE, Ohio, September 21, 2010 /PRNewswire/ -- Omega Laboratories, Inc. today announced that it has received accreditation for forensic drug testing of hair from the Commission on Laboratory Accreditation of the College of American Pathologists (CAP). During the CAP accreditation process, inspectors carefully review the laboratory&rsquo;s records and quality control procedures for the preceding two years, as well as the laboratory&rsquo;s equipment, facilities, safety program and record. CAP inspectors also examine laboratory staff qualifications and the overall management of the laboratory. This stringent inspection program is designed to ensure the highest standard of care for all laboratory clients. Omega Laboratories is only one of two laboratories in the world to receive this prestigious accreditation for drug testing in hair.
&ldquo;In the past Omega has received accreditation from CAP for urine testing, but we have shifted our focus to utilize our expertise in hair testing,&rdquo; said Dr. John Vitullo, CEO of Omega Laboratories. &ldquo;We were pleased to see CAP has responded to the increasing demand for hair testing and added it to its accreditation program. This accreditation is one more way Omega maintains its position as an industry leader.&rdquo;
&ldquo;We are especially proud of the CAP accreditation,&rdquo; continues Dr. Vitullo, &ldquo;because it specifically covers all facets of the hair testing laboratory procedure, including screening, extraction and confirmation.&rdquo; This detailed examination of the testing process also included a complete review of Omega&rsquo;s hair wash procedure for removing external contaminants.
The addition of CAP accreditation further positions Omega Laboratories as a worldwide leader in hair testing for drugs of abuse. Omega&rsquo;s qualifications include:
<ul>
<li>ISO/IEC 17025 Laboratory Accreditation &ndash; Currently the only drugs of abuse laboratory in the United States with this accreditation.</li>
<li>ISO/IEC 17025 Forensic Quality Services (FQS) &ndash; Special designation for forensic/court testing.</li>
<li>FDA Clearance &ndash; Proven capability to obtain voluntary clearance of screening assays.</li>
<li>Certification by other industry groups such as CLIA and New York State Department of Health.</li>
<li>Proficiency Testing &ndash; Participation in Society of Hair Testing (SOFT), German Society of Toxicological and Forensic Chemistry (GTFCh) hair testing proficiency programs.</li>
</ul>
About CAP - The College of American Pathologists is a medical society that serves more than 17,000 physician members and the laboratory community throughout the world. It is the world's largest association composed exclusively of Board-certified pathologists and is widely considered the leader in laboratory quality assurance. The College is an advocate for high-quality and cost-effective patient care. More information about the College can be found at www.cap.org.

Omega Laboratories, Inc. today announced that it has received accreditation for forensic drug testing of hair from the Commission on Laboratory Accreditation of the College of American Pathologists (CAP).

Omega Laboratories Awarded CAP Accreditation for Drug Testing of Hair

Mogadore, Ohio, December 20, 2011 / PRNewswire/ -- Omega Laboratories, Inc. announced that it has become the first and only laboratory to receive 510(k) clearance from the Food and Drug Administration (FDA) for its Extended Opiates Test that detects the use of Oxycodone and Hydrocodone through human hair analysis. The clearance also included the test for Codeine, Morphine and Heroin.
The ability to test for Oxycodone (eg. OxyContin&reg; and Percocet&reg;)* and Hydrocodone (eg. Vicodin&reg; and Lortab&reg;)* has become increasingly important to organizations as prescription drug abuse continues to rise, and has been recognized as a serious and growing health problem. A recent report by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) found that use of prescription pain relievers without a doctor's prescription, or for nonmedical use, is the second most common form of illicit drug use in the United States.
As stated at a meeting of the U.S. Department of Health and Human Service&rsquo;s Drug Testing Advisory Board (DTAB) in January of this year, the DTAB views this type of clearance as a key component in the future adoption of hair testing to Federal Workplace Drug Testing Programs. In addition, many companies regulated by Federal Guidelines, like the U.S. Department of Transportation&rsquo;s 49 CFR Part 40, have come to rely on Extended Opiates testing in hair samples because they realize prescription opiate abuse is a critical workplace safety issue. Regulated companies that have safety-sensitive positions, such as motor carriers, pipeline/energy, nuclear power and railroads, are able to conduct expanded drug testing programs under company authority and often do so because of the inherent flaws in the current urine based testing program.
&ldquo;At Omega we are focused on providing the highest-quality and most reliable testing procedure available,&rdquo; said Dr. John Vitullo, CEO of Omega Laboratories. &ldquo;This clearance means that we offer our clients an unsurpassed level of expertise and proficiency in our hair testing for drugs of abuse process. This clearance is one more way Omega maintains its position as the industry leader in testing expertise and customer service.&rdquo;
Omega&rsquo;s 510(k) FDA submission contained over 13,000 pages and included extensive studies involving precision, agreement, stability, recovery, effects of contamination, and the effects of different hair cosmetic treatments including multiple coloring products, straighteners/relaxers, and shampoos marketed to evade a drug test. Hair color, curvature and ethnic origin of the samples were also analyzed to ensure that a diverse population was represented in the studies. A shipping study was performed showing there were no effects to the hair samples from extreme temperature and humidity changes, unlike the problems that have plagued the transport of urine samples.
&ldquo;In addition to being the only hair testing laboratory with clearance for an Oxycodone and Hydrocodone test, Omega was the first hair testing laboratory in the United States accredited to the ISO/IEC 17025 standard,&rdquo; said Dr. Vitullo. &ldquo;Accrediting agencies have referred to ISO/IEC 17025 as the gold standard of laboratory accreditation, and we feel strongly that it is the most comprehensive quality process available to our industry.&rdquo;
According to the January 2009 FDA Guidance Document entitled Submission of Laboratory Packages by Accredited Laboratories, &ldquo;ISO/IEC 17025 is the most widely used laboratory standard for federal testing laboratories, including FDA&rsquo;s own laboratories, and ISO/IEC 17025 is internationally recognized and accepted world-wide."&nbsp;

Omega Laboratories, Inc. announced that it has become the first and only laboratory to receive 510(k) clearance from the Food and Drug Administration (FDA) for its Extended Opiates Test that detects the use of Oxycodone and Hydrocodone through human hair analysis. The clearance also included the test for Codeine, Morphine and Heroin.

Omega Laboratories Becomes the First Laboratory to Receive 510(k) Clearance for Oxycodone and Hydrocodone Drugs of Abuse Test for Hair

We have been notified that FedEx is experiencing delays today. Please check your tracking number for the most up-to-date delivery information.We apologize for any inconvenience and appreciate your patience as we work to expedite the processing of your samples once they arrive.-- Visit <a href="https://status.omegalabs.net" rel="noopener noreferrer nofollow" data-link-auto="">https://status.omegalabs.net</a> for information on the recently publicized PHP2Shell vulnerabilities and why they do not affect Omega Laboratories.

SAMPLE SHIPMENT DELAYS - October 23, 2026

Recent reports have identified cybersecurity vulnerabilities affecting some organizations worldwide that use a specific web-development technology known as PHP.Omega Laboratories does not use this technology in its core laboratory systems, client portals, or specimen management platforms. Therefore, these vulnerabilities do not affect Omega's services, systems, or customer data.There is no risk to specimen, donor, or client information related to this issue.We continue to monitor cybersecurity threats and maintain robust safeguards to protect the security and privacy of customer information.

ATTENTION

Omega Laboratories will be closed on Thursday, December 24th through Friday, December 25th for the holidays, so that our staff can celebrate with their families. We appreciate your understanding and wish you a safe holiday!

HOLIDAY CLOSURE

Omega Laboratories will be closed on Thursday, November 26th so that our staff can celebrate the Thanksgiving holiday with their families. We will open again on Friday, November 27th. We appreciate your understanding and wish you a safe holiday!

Omega Laboratories will be closed on Monday, September 7th for Labor Day. We appreciate your understanding and wish you a safe holiday!

In observance of the Independence Day holiday, Omega Laboratories will be closed on Friday, July 3rd. We appreciate your understanding and wish you a safe holiday!

We are currently experiencing technical difficulties with our phone system affecting connectivity. If this is an urgent matter, you can e-mail us at <a href="mailto:CustomerService@Omegalabs.net" rel="noopener noreferrer nofollow" data-link-auto="">CustomerService@Omegalabs.net</a> and we will get back to you as soon as possible. We apologize for any inconvenience and hope to have the issue resolved soon.

SAMPLE SHIPMENT DELAYS - October 23, 2026

A Leading Provider of Drug & Alcohol Testing Solutions

Omega Laboratories and Cannabix Technologies Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection

Omega News

Omega Laboratories and Cannabix Technologies Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection

News: Omega Laboratories Ranks #1 for Most Recognized Hair Testing Brand for the 5th year

Omega and Cannabix announce peer-reviewed publication on THC Breath Testing in the Journal of Analytical Toxicology